SCYNEXIS to Join Major Investment Conference
SCYNEXIS, Inc. (NASDAQ: SCYX), a prominent biotechnology firm focused on creating innovative treatments for challenging and drug-resistant infections, has announced that Dr. David Angulo, M.D., the President and CEO, will participate in the H. C. Wainwright 26th Annual Global Investment Conference. This important event is scheduled for Wednesday, September 11, at 10:00 A.M. ET.
About the H. C. Wainwright Conference
This esteemed investment conference provides a platform for biotechnology companies to present their latest innovations and strategic initiatives. During the event, Dr. Angulo will give a corporate presentation outlining SCYNEXIS's ongoing efforts to combat drug-resistant infections and will also hold one-on-one meetings with potential investors.
Format and Structure of the Conference
The conference will feature a live presentation, along with opportunities for individual meetings. These interactions are vital for building relationships and sharing insights with investors interested in innovative healthcare solutions.
The Importance of SCYNEXIS's Innovations
SCYNEXIS is leading the way in developing proprietary solutions to tackle the growing issue of drug-resistant infections, which increasingly impact patient outcomes worldwide. The company's advanced antifungal platform, referred to as "fungerps," plays a crucial role in its initiatives.
Innovations from SCYNEXIS
One of SCYNEXIS's groundbreaking products is ibrexafungerp, the first offering from the fungerp platform, which has been successfully licensed to GSK. In June 2021, the U.S. FDA approved BREXAFEMME (ibrexafungerp tablets) for treating vulvovaginal candidiasis (VVC). Additionally, in November 2022, a second indication was approved to help reduce the recurrence of VVC, showcasing the company's ongoing success in development.
Current Clinical Trials
SCYNEXIS is currently conducting late-stage clinical trials to investigate ibrexafungerp’s potential for treating serious invasive fungal infections in hospitalized patients. This critical research underscores the company's dedication to addressing urgent medical needs.
Further Antifungal Developments
Beyond ibrexafungerp, SCYNEXIS is advancing its research pipeline with several other antifungal agents from the same class, which are in pre-clinical stages alongside other discovery projects. A notable compound in development is SCY-247.
Commitment and Future Goals of SCYNEXIS
SCYNEXIS is committed to developing innovative treatments that can benefit millions of patients around the globe. By participating in significant industry events like the H. C. Wainwright Conference, the company seeks to strengthen its connections with investors and stakeholders who share its passion for improving treatment options for challenging infections.
Contacting SCYNEXIS
For those seeking more information about SCYNEXIS and its exciting advancements, inquiries can be directed to their investor relations contact. Irina Koffler of LifeSci Advisors is available for questions and can be reached at (646) 970-4681 or via email.
Frequently Asked Questions
What is the main focus of SCYNEXIS?
SCYNEXIS is dedicated to developing innovative medicines for difficult-to-treat and drug-resistant infections.
When is SCYNEXIS presenting at the investment conference?
SCYNEXIS will present at the H. C. Wainwright 26th Annual Global Investment Conference on September 11 at 10:00 A.M. ET.
What are the key products developed by SCYNEXIS?
One of SCYNEXIS's key products is ibrexafungerp, which has received FDA approval for treating vulvovaginal candidiasis.
How does SCYNEXIS address drug-resistant infections?
SCYNEXIS develops a proprietary antifungal platform, "fungerps," which includes ibrexafungerp and other investigational compounds.
Who can I contact for more information about SCYNEXIS?
For inquiries, you can contact Irina Koffler at LifeSci Advisors, Tel: (646) 970-4681.
